利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.037 秒)

    Viral complement control proteins for eye disorders
    3.
    发明授权
    Viral complement control proteins for eye disorders 失效
    用于眼睛疾病的病毒补体对照蛋白

    公开(公告)号：US08043609B2

    公开(公告)日：2011-10-25

    申请号：US11612751

    申请日：2006-12-19

    申请人： Pascal Deschatelets ,  Paul Olson ,  Cedric Francois

    发明人： Pascal Deschatelets ,  Paul Olson ,  Cedric Francois

    IPC分类号： A61K35/00 ,  C07K5/00

    CPC分类号： A61K38/162 ,  A61K9/0051 ,  A61K38/17

    摘要： The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.

    摘要翻译： 本发明提供用于治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性或脉络膜新生血管形成，眼部炎症或其任何组合的其它病症的组合物和方法。 某些组合物包含痘病毒补体对照蛋白或其补体结合片段或变体。 其他组合物包含与结合存在于细胞或非细胞分子实体的表面或其表面上的组分连接的部分的痘病毒补体对照蛋白，例如存在于患有年龄相关性黄斑的风险的患者的眼睛中的组分 变性或相关病症或脉络膜新生血管形成，眼部炎症或这些的任何组合。 某些方法包括向受试者施用痘病毒补体对照蛋白或补体结合片段或其变体。

    COMPOSITIONS AND METHODS FOR TREATMENT OF TRAUMA
    4.
    发明申请
    COMPOSITIONS AND METHODS FOR TREATMENT OF TRAUMA 审中-公开
    组合物和治疗TRAUMA的方法

    公开(公告)号：US20110092446A1

    公开(公告)日：2011-04-21

    申请号：US12669957

    申请日：2008-07-21

    申请人： Cedric Francois ,  Pascal Deschatelets ,  Paul Olson

    发明人： Cedric Francois ,  Pascal Deschatelets ,  Paul Olson

    IPC分类号： A61K38/12 ,  C12Q1/68 ,  C07K7/64

    CPC分类号： A61K38/12 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156

    摘要： The present invention features the use of a complement inhibitor, e.g., a compstatin analog for treating an individual who has suffered a severe injury. In some embodiments, the complement inhibitor may be administered within 24 hours following the injury and optionally also at later time points. The complement inhibitor may, for example, be administered prior to transporting the patient to a health care facility, during transport of the patient to a health care facility, or in the emergency department. Further provided are methods of selecting individuals for such therapy. Further provided are methods of identifying individuals at increased risk of poor outcome following trauma. In certain embodiments the methods comprise determining whether the genotype of the patient includes an allele of a polymorphism in or near a complement-related gene, wherein said allele is associated with risk of poor outcome following trauma.

    摘要翻译： 本发明的特征在于补体抑制剂例如化合物类似物用于治疗遭受严重损伤的个体的用途。 在一些实施方案中，补体抑制剂可以在损伤后24小时内和任选地也在稍后的时间点施用。 例如，补体抑制剂可以在将患者运送到保健设施之前，在将患者运送到保健设施或急诊部门期间进行给药。 还提供了选择这种治疗的个体的方法。 进一步提供的是识别创伤后不良结局风险增加的个体的方法。 在某些实施方案中，所述方法包括确定患者的基因型是否包括在补体相关基因中或其附近的多态性的等位基因，其中所述等位基因与创伤后的结果不良的风险相关。

    Compositions and methods for enhancing phagocytosis or phagocyte activity
    5.
    发明授权
    Compositions and methods for enhancing phagocytosis or phagocyte activity 有权
    用于增强吞噬作用或吞噬细胞活性的组合物和方法

    公开(公告)号：US08198020B2

    公开(公告)日：2012-06-12

    申请号：US10923940

    申请日：2004-08-23

    申请人： Cedric Francois ,  Pascal Deschatelets ,  Paul Olson ,  Alec Machiels

    发明人： Cedric Francois ,  Pascal Deschatelets ,  Paul Olson ,  Alec Machiels

    IPC分类号： C12Q1/70 ,  C12Q1/00 ,  G01N33/53 ,  G01N33/567 ,  G01N33/574

    CPC分类号： B82Y5/00 ,  A61K47/544 ,  A61K47/62 ,  A61K47/6911 ,  A61K47/6913

    摘要： The present invention provides a system for enhancing clearance or destruction of undesirable cells or noncellular molecular entities by tagging such cells or noncellular molecular entities with a marker that targets the cells or noncellular molecular entities for phagocytosis (phagocytic marker). The target cells can be, for example, endothelial cells, tumor cells, leukocytes, or virus-infected cells. In certain embodiments of the invention the tagging is accomplished by administering a composition comprising an antibody or ligand linked to the phagcytotic marker, wherein the antibody or ligand binds to a cell type specific marker present on or in the cell surface of a target cell. In preferred embodiments of the invention, the phagocytic marker comprises phosphatidylserine or a group derived from phosphatidylserine, thrombospondin-1, annexin I, or a derivative of any of these.

    摘要翻译： 本发明提供了一种用于通过用靶向细胞或非细胞分子实体进行吞噬作用（吞噬标记）的标记来标记这样的细胞或非细胞分子实体来增强不需要的细胞或非细胞分子实体的清除或破坏的系统。 靶细胞可以是例如内皮细胞，肿瘤细胞，白细胞或病毒感染的细胞。 在本发明的某些实施方案中，标记通过施用包含与噬菌体标记物连接的抗体或配体的组合物来实现，其中所述抗体或配体结合存在于靶细胞的细胞表面上或细胞表面的细胞类型特异性标志物。 在本发明的优选实施方案中，吞噬标记物包含磷脂酰丝氨酸或衍生自磷脂酰丝氨酸，血小板反应素-1，膜联蛋白I或其任何衍生物的基团。

    Viral Complement Control Proteins for Eye Disorders
    6.
    发明申请
    Viral Complement Control Proteins for Eye Disorders 失效
    用于眼部疾病的病毒补体控制蛋白

    公开(公告)号：US20080075755A1

    公开(公告)日：2008-03-27

    申请号：US11612751

    申请日：2006-12-19

    申请人： Pascal Deschatelets ,  Paul Olson ,  Cedric Francois

    发明人： Pascal Deschatelets ,  Paul Olson ,  Cedric Francois

    IPC分类号： A61K38/16 ,  A61K9/00 ,  A61P27/02

    CPC分类号： A61K38/162 ,  A61K9/0051 ,  A61K38/17

    摘要： The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.

    摘要翻译： 本发明提供用于治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性或脉络膜新生血管形成，眼部炎症或其任何组合的其它病症的组合物和方法。 某些组合物包含痘病毒补体对照蛋白或其补体结合片段或变体。 其他组合物包含与结合存在于细胞或非细胞分子实体的表面或其表面上的组分连接的部分的痘病毒补体对照蛋白，例如存在于患有年龄相关性黄斑的风险的患者的眼睛中的组分 变性或相关病症或脉络膜新生血管形成，眼部炎症或这些的任何组合。 某些方法包括向受试者施用痘病毒补体对照蛋白或补体结合片段或其变体。